| Literature DB >> 29569937 |
Leila Kafshdooz1,2, Hojjat Pourfathi3, Abolfazl Akbarzadeh4,5,6, Taiebeh Kafshdooz7, Zohre Razban1, Roghayeh Sheervalilou8, Naser Ebrahimi Sadr9, Rovshan Khalilov10,11, Siamak Saghfi10,11, Taras Kavetskyy10,12,13, Lala Mammadova14, Masoud Mehrizadeh15, Samaneh Ghasemali7.
Abstract
MicroRNAs (miRNAs) have had a revolutionary impact on cancer research over the recent years. They emerge as important players in tumourigenesis, leading to a paradigm shift in oncology. Ovarian cancer is the leading cause of death among gynaecologic malignancies. Therefore, there is a strong need for prognostic and predictive markers for early diagnosis which helps optimize and personalize treatment. Asymptomatically, ovarian cancer is often diagnosed at advanced and incurable stages. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given miRNAs importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability and accumulation at the tumour site. Although many obstacles need to be overcome, miRNA therapy could be a powerful tool for ovarian cancer prevention and treatment. In this review, we discuss about the emerging roles of miRNAs in various aspects of ovarian cancer.Entities:
Keywords: Ovarian cancer; microRNAs; nanoformulations; nanoparticles
Mesh:
Substances:
Year: 2018 PMID: 29569937 DOI: 10.1080/21691401.2018.1454931
Source DB: PubMed Journal: Artif Cells Nanomed Biotechnol ISSN: 2169-1401 Impact factor: 5.678